Stephens lowered the firm’s price target on Evolent Health (EVH) to $12 from $16 and keeps an Equal Weight rating on the shares. The firm is negatively revising its Q4 and FY25E EBITDA estimates, but believes visibility is high on revenue, profits, and OpEx for the remainder of the business beyond the Performance Suite business, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $14 from $27 at UBS
- Evolent Health reiterates long-term outlook, says FY25 guide coming February 20
- Evolent dips after Truist warns guidance may be ‘significantly’ below consensus
- Evolent Health price target lowered to $17 from $20 at RBC Capital
- Evolent Health to Present at J.P. Morgan Conference